BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villani A, Ravaro S, Cerea P, Caravita S, Ciambellotti F, Branzi G, Munforti C, Parati G, Malfatto G. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration? J Cardiovasc Med (Hagerstown) 2020;21:682-7. [PMID: 32744827 DOI: 10.2459/JCM.0000000000001000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Mustafa NH, Jalil J, Zainalabidin S, Saleh MS, Asmadi AY, Kamisah Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. Front Pharmacol 2022;13:892460. [DOI: 10.3389/fphar.2022.892460] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zhang J, Du L, Qin X, Guo X. Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies. J Am Heart Assoc 2022;:e024449. [PMID: 35470677 DOI: 10.1161/JAHA.121.024449] [Reference Citation Analysis]
3 Gentile P, Cantone R, Perna E, Ammirati E, Varrenti M, D'angelo L, Verde A, Foti G, Masciocco G, Garascia A, Frigerio M, Cipriani M. Haemodynamic effects of sacubitril/valsartan in advanced heart failure. ESC Heart Failure. [DOI: 10.1002/ehf2.13755] [Reference Citation Analysis]
4 Mandal AKJ, Missouris CG. Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction. J Cardiovasc Med (Hagerstown) 2021;22:233-4. [PMID: 32925393 DOI: 10.2459/JCM.0000000000001111] [Reference Citation Analysis]
5 Malfatto G, Villani A, Parati G. Heart failure features and sacubitril/valsartan effects. J Cardiovasc Med (Hagerstown) 2021;22:234-5. [PMID: 33136813 DOI: 10.2459/JCM.0000000000001128] [Reference Citation Analysis]